V930

BIOLOGICAL3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

CancerCancers Expressing HER-2 and/or CEAHealthy

Phase 1

V930 First in Man (FIM) Study (V930-002)(COMPLETED)

CompletedNCT00250419

Merck Sharp & Dohme LLCCancers Expressing HER-2 and/or CEA

Start: 2005-09-30End: 2008-09-30Updated: 2015-02-10

A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

CompletedNCT00647114

Merck Sharp & Dohme LLCCancer

Start: 2007-08-31End: 2009-04-30Updated: 2015-03-13

A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001)

CompletedNCT00721461

Merck Sharp & Dohme LLCHealthy

Start: 2005-07-31End: 2005-10-31Updated: 2015-08-04

Related Papers

Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.

2013-03-0864 citations